Management of anti-D prophylaxis in RhD negative women undergoing early medical abortion – an international practice survey among practitioners

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159384" target="_blank" >RIV/00098892:_____/25:10159384 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/25:73633021

Result on the web

<a href="https://www.tandfonline.com/doi/full/10.1080/13625187.2025.2486690#abstract" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/13625187.2025.2486690#abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/13625187.2025.2486690" target="_blank" >10.1080/13625187.2025.2486690</a>

Result language

angličtina

Original language name

Management of anti-D prophylaxis in RhD negative women undergoing early medical abortion – an international practice survey among practitioners

Original language description

Aim: We evaluated the current practices of abortion providers giving anti-D prophylaxis to RhD negative women undergoing first trimester medical abortion and factors that influenced the decision. We also examined RhD management strategies that could be safely adopted. Methods: A Steering Committee of abortion providers drafted a questionnaire on anti-D prophylaxis practices and perceptions. The 28-question survey, hosted online from December 2022 to December 2023, targeted international abortion providers. Results: Almost 62% of respondents perform medical abortion during the first trimester (up to 12 weeks of amenorrhoea [WA]), while 32.8% provide it during the second trimester (13 to 26 WA). Among providers, 55.8% administer anti-D prophylaxis to all RhD negative women during first trimester medical abortions, 25.5% provide it selectively, and 18.6% do not administer it at all. Providers who do not administer IgG anti-D rely on national guidelines (51.2%), hospital protocols (16.3%), or both (7.0%), citing early gestational age (36.5%) and insufficient evidence (22.9%) as reasons. The primary reason for administering IgG anti-D was preventing risks in future pregnancies (52.7%). Yet, 59.1% expressed interest in changing their anti-D prophylaxis practices during early abortion. Conclusion: This study highlights the huge variations in anti-D prophylaxis practices during first trimester medical abortion. These discrepancies mirror differences in national and international guidelines and underscore the need for robust clinical evidence to determine the gestational age limits for alloimmunization risk and support protocol updates.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30214 - Obstetrics and gynaecology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The European Journal of Contraception and Reproductive Health Care

ISSN

1362-5187

e-ISSN

1473-0782

Volume of the periodical

30

Issue of the periodical within the volume

4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

205-215

UT code for WoS article

001472319200001

EID of the result in the Scopus database

2-s2.0-105003250290